<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574196</url>
  </required_header>
  <id_info>
    <org_study_id>1108162</org_study_id>
    <secondary_id>2011-A01357-34</secondary_id>
    <nct_id>NCT01574196</nct_id>
  </id_info>
  <brief_title>Assessment of Cardiac Autonomic Function in Adulthood After Chemotherapy or Radiotherapy in Childhood</brief_title>
  <acronym>SALTO-SNA</acronym>
  <official_title>Assessment of Cardiac Autonomic Function in Adulthood After Chemotherapy or Radiotherapy in Childhood. Ancillary Study of the &quot;Long-term Follow-up of Childhood Cancer Survivors in the Rhône-Alpes and Auvergne Regions of France&quot; Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SALTO-SNA study is an ancillary study of the SALTO study (Suivi À Long Terme en Oncologie
      des enfants guéris d'un cancer pédiatrique en régions Rhône-Alpes et Auvergne) coordinated by
      Dr. Claire Berger, pediatric oncologist at the CHU, Saint Etienne. It aims at re-examining,
      in their initial treatment center, all patients (a cohort of 495 patients alive in 2011),
      diagnosed between 1987 and 1992, and cured of childhood cancer (except leukemia) in the
      Rhône-Alpes and Auvergne regions.

      The rationale for this study is based on the observation that although the survival rate of
      childhood cancers has now reached 75%, complications of chemotherapy and radiotherapy are
      high and greatly increase the risk of mortality in later years (estimated to be 14% in the
      literature).

      The morbidity risk of chemotherapy and radiotherapy can be quantified by assessing the
      activity of the intrinsic cardiac autonomic regulation, which represents a powerful predictor
      of cardiovascular morbidity to the individual.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For this purpose, analysis of the cardiac RR variability is a reliable, non-invasive and
      reproducible system that could be used in this population as a tool for early detection of
      cardiovascular dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Autonomic nervous system activity</measure>
    <time_frame>15 years after the end of the cancer treatment</time_frame>
    <description>The autonomic status will be classified in sympatho-vagal equilibrium as &quot;normal&quot;, &quot;altered&quot; or &quot;severely abnormal&quot; according to the values obtained for some temporal indices (SDNN, SDaNN, RMSSD etc. ..) and frequencies (Ptot, HF, LF , VLF, ratio LF / HF) compared to validated standards for the age (mean +/- standard deviation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Doses of radiotherapy</measure>
    <time_frame>15 years after the end of the cancer treatment</time_frame>
    <description>Regarding radiotherapy, the doses of different vital organs of the body (151 anatomic sites) will be estimated from the radiotherapy technical records with the help of the Dos-EG software proposed by the INSERM team of F De Vathaire.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">83</enrollment>
  <condition>Cancer</condition>
  <condition>Sequels</condition>
  <condition>Complications</condition>
  <condition>Autonomic Nervous System</condition>
  <arm_group>
    <arm_group_label>Young adult survivors of childhood cancer</arm_group_label>
    <description>Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autonomic nervous system activity records</intervention_name>
    <description>The description of autonomic equilibrium is based on the use of non-invasive tools such as Holter-ECG monitor (24 hours) which is suitable for longitudinal follow up of cohorts of patients. This tool allows the analysis of instantaneous or delayed variability of the heart rate, in the Hertzian frequency domain after extraction and mathematical transformation of a temporal sequence of R-R spaces from the ECG signal.</description>
    <arm_group_label>Young adult survivors of childhood cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a prospective cohort study in non-leukemia cancer survivors diagnosed between 1987
        and 1992 in the Rhône-Alpes and Auvergne regions of France, who were younger than 15 years
        at the time of diagnosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Included in the SALTO study

          -  Having signed the informed consent form

        Exclusion Criteria:

          -  General anesthesia in the two weeks prior to recording

          -  Known allergy to electrodes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire BERGER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugues PATURAL, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHOP</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Childhood cancer</keyword>
  <keyword>Cancer</keyword>
  <keyword>Sequels</keyword>
  <keyword>Complications</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Surgery</keyword>
  <keyword>Autonomic nervous system</keyword>
  <keyword>Parasympathetic Nervous System</keyword>
  <keyword>Sympathetic Nervous System</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

